This study presents an important finding on the role of GATA4 in aging and OA-associated cartilage pathology. The evidence supporting the conclusions is compelling, with rigorous in vitro and in vivo ...

The global lentiviral vector CDMO market is set to witness a growth rate of 8% in the next 5 years. Growing demand for gene and cell therapies; expanding pipeline of gene therapy products; ...

The lentiviral vector market is rapidly growing, driven by advancements in gene therapy and increasing demand for innovative medical treatments. In 2023, the market was valued at USD 176.8 million and ...

Lentiviral transduction is a popular and powerful gene delivery method for downstream applications such as cell line generation, therapeutic model generation and CAR-T research. However, current ...

One of the key components of CAR-T therapy is lentivirus, which is used to modify the patient's immune cells. Lentivirus manufacturing accounts for about 50% of the therapy's overall cost, making it a ...

Autologous HSCs were transduced with CD68-ET3-LV — a lentiviral vector including a new F8 transgene (ET3) with a myeloid-directed CD68 promoter — either without transduction enhancer (group 1 ...

Lentivirus is a genus in the family of Retroviridae ... which are responsible for structural and enzymatic components.

Oxford, UK – 15 May 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the launch of its 4 th generation ...

The company’s manufacturing capabilities include both adeno-associated viral vectors and lentiviral vectors. Other companies have emerged to fill viral vector manufacturing needs. Lentiviral ...